Format

Send to

Choose Destination
N Engl J Med. 2014 Sep 4;371(10):906-17. doi: 10.1056/NEJMoa1402551.

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.

Collaborators (225)

Forsyth C, Presgrave P, Szer J, Durrant S, Campbell P, Mollee P, Coghlan D, Wellwood J, Cannell P, Prince M, Eek R, Horvath N, Harrison S, Renwick W, Thaler J, Petzer A, Kasparu H, Bauernhofer T, Meran J, Fridrik M, Balcke P, Gisslinger H, Greil R, Doyen C, Meuleman N, Pierre P, Vekemans M, Demuynck H, Wu K, Van Droogenbroeck J, Schots R, Offner F, Van de Velde A, Leblanc R, Tosikyan A, Shustik C, Song K, Lemieux B, Minuk L, Lalancette M, Cheung M, Noble M, Vanderjagt R, Desjardins P, Aucoin N, Dueck G, Yee A, Reiman A, Kouroukis T, Assouline S, Al-Tourah A, Lu J, Chen W, Liu T, Shen Z, Alexis M, Assouline D, Audhuy B, Azais I, Belhadj K, Benramdane R, Tempescul A, Boue F, Rose C, Bourhis J, Bouscary D, Caillot D, Casassus P, De Renzis B, Genet P, De Revel T, Dib M, Dorvaux V, Etienne G, Gabriel E, Eisenmann J, Fitoussi O, Garderet L, Gaspard M, Sebban C, Glaisner S, Griffoul I, Decaux O, Herbrecht R, Jaccard A, Jardel H, Kaphan R, Kolb B, Barbe M, Laribi K, Lenain P, Macro M, Maisonneuve H, Pavy S, Marit G, Michallet M, Allangbam O, Mosser L, Pegourie B, Rigaudeau S, Rodon P, Rossi J, Royer B, Eschard J, Stoppa A, Suc E, Thyss A, Salles G, Vilque J, Voillat L, Voog E, Wetterwald M, Zarnitsky C, Junghanss C, Dührsen U, Fenk R, Rummel M, Derigs HG, Zeis M, Mügge L, Ottmann O, Ostermann H, Kropff M, Niederwieser D, Langer C, Röllig C, Panagiotidis P, Corso A, Di Renzo N, Foa R, Fragasso A, Canepa L, Martinelli G, Gamberi B, Musso M, Petrini M, Pisani F, Quarta G, Sacchi S, Tassone P, Lazzaro A, Ciceri F, Browett P, Romeril K, Butler A, Parreira J, Martins A, Herlander M, Gonçalves C, Lee JH, Yoon S, Eom H, Jo D, Kwak J, Ryoo H, Lee J, Kim SJ, Min CK, Suh C, Kim K, Lee W, Mun Y, Kim HJ, Lahuerta-Palacios JJ, Lleonart J, Gonzalez MS, Bermudez-Rodriguez A, de la Fuente F, Mateo-Morales M, Gonzalez-Montes Y, Hernandez-Maraver D, Clapés V, Prosper-Cardoso F, Ramírez G, Casasus A, Granell M, Giraldo-Castellano P, Echeveste-Gutierrez A, Palomera-Bernal L, Nahi H, Gruber A, Sjöö F, Leyvraz S, Pabst T, Heim D, Bargetzi M, Cathomas R, Huang S, Yeh S, Chiou T, Ezaydi Y, Littlewood T, Knechtli C, McQuaker G, Fegan C, Mehta A, Bird J, Ashcroft J, Kazmi M, Hunter H, Cook M, Crawley C, Basu S, Hall R, Seale J, Bensinger W, Coutre S, Priego V, Martin T, Kaplan H, Tirumali N, Dakhil S, Gupta M, Jacobson R, Vogl D, Moezi M, Gravenor D, Yunus F, Guthrie T, Reu F, Catchatourian R, Gabrail N, Nieva J, De la Puerta M, Ryan H.

Author information

1
The authors' affiliations are listed in the Appendix.

Abstract

BACKGROUND:

The combination melphalan-prednisone-thalidomide (MPT) is considered a standard therapy for patients with myeloma who are ineligible for stem-cell transplantation. However, emerging data on the use of lenalidomide and low-dose dexamethasone warrant a prospective comparison of the two approaches.

METHODS:

We randomly assigned 1623 patients to lenalidomide and dexamethasone in 28-day cycles until disease progression (535 patients), to the same combination for 72 weeks (18 cycles; 541 patients), or to MPT for 72 weeks (547 patients). The primary end point was progression-free survival with continuous lenalidomide-dexamethasone versus MPT.

RESULTS:

The median progression-free survival was 25.5 months with continuous lenalidomide-dexamethasone, 20.7 months with 18 cycles of lenalidomide-dexamethasone, and 21.2 months with MPT (hazard ratio for the risk of progression or death, 0.72 for continuous lenalidomide-dexamethasone vs. MPT and 0.70 for continuous lenalidomide-dexamethasone vs. 18 cycles of lenalidomide-dexamethasone; P<0.001 for both comparisons). Continuous lenalidomide-dexamethasone was superior to MPT for all secondary efficacy end points, including overall survival (at the interim analysis). Overall survival at 4 years was 59% with continuous lenalidomide-dexamethasone, 56% with 18 cycles of lenalidomide-dexamethasone, and 51% with MPT. Grade 3 or 4 adverse events were somewhat less frequent with continuous lenalidomide-dexamethasone than with MPT (70% vs. 78%). As compared with MPT, continuous lenalidomide-dexamethasone was associated with fewer hematologic and neurologic toxic events, a moderate increase in infections, and fewer second primary hematologic cancers.

CONCLUSIONS:

As compared with MPT, continuous lenalidomide-dexamethasone given until disease progression was associated with a significant improvement in progression-free survival, with an overall survival benefit at the interim analysis, among patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation. (Funded by Intergroupe, Francophone du Myélome and Celgene; FIRST ClinicalTrials.gov number, NCT00689936; European Union Drug Regulating Authorities Clinical Trials number, 2007-004823-39.).

Comment in

PMID:
25184863
DOI:
10.1056/NEJMoa1402551
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center